The relationships among monocyte subsets,miRNAs and inflammatory cytokines in patients with acute myocardial infarction

Background

Acute myocardial infarction (AMI) causes irreversible myocardial damage and release of inflammatory mediators, including cytokines, chemokines and miRNAs. We aimed to investigate changes in the levels of cytokines (IL-6, TNF-α and IL-10), miRNAs profiles (miR-146 and miR-155) and distribution of different monocyte subsets (CD14++CD16-, CD14++CD16+, CD14+CD16++) in the acute and post-healing phases of AMI.

Hedgehog signaling inhibitors in solid and hematological cancers

BackgroundThe hedgehog signaling pathway is normally tightly regulated. Mutations in hedgehog pathway components may lead to abnormal activation. Aberrantly activated hedgehog signaling plays a major role in the development of solid and hematological cancer. In recent years, inhibitors have been developed that attenuate hedgehog signaling; 2 have been approved for use in basal cell carcinoma (BCC), while others are under development or in clinical trials. The aim of this review is to provide an overview of known hedgehog inhibitors (HHIs) and their potential for the treatment of hematological cancers and solid tumors beyond BCC.DesignPublished literature was searched to identify articles relating to HHIs in noncutaneous cancer. Both preclinical and clinical research articles were included. In addition, relevant clinical trial results were identified from www.clinicaltrials.gov. Information on the pharmacology of HHIs is also included.ResultsHHIs show activity in a variety of solid and hematological cancers. In preclinical studies, HHIs demonstrated efficacy in pancreatic cancer, rhabdomyosarcoma, breast cancer, and acute myeloid leukemia (AML). In clinical studies, HHIs showed activity in medulloblastoma, as well as prostate, pancreatic, and hematological cancers. Current clinical trials testing the efficacy of HHIs are underway for prostate, pancreatic, and breast cancers, as well as multiple myeloma and AML.ConclusionsAs clinical trial results become available, it will be possible to discern which additional tumor types are suited to HHI mono- or combination therapy with other anticancer agents. The latter strategy may be useful for delaying or overcoming drug resistance.     

右归丸经IL-6/STAT3信号通路对膝骨关节炎模型大鼠软骨组织退变的调控机制

目的:观察右归丸对膝骨关节炎(KOA)模型鼠软骨组织信号转导和转录激活因子3(STAT3)和白细胞介素-6(IL-6)表达水平的影响。方法:将大鼠随机分为假手术组、模型组、硫酸氨基葡萄糖组、右归丸高、中、低剂量组,每组10只。采用改良Hulth法制备大鼠KOA模型,假手术组和模型组给予等体积生理盐水灌胃,右归丸高、中、低剂量组分别给予右归丸4.8,2.4,1.2 g·kg^-1灌胃,硫酸氨基葡萄糖组给予硫酸氨基葡萄糖0.17 g·kg^-1灌胃,连续给药8周。干预结束24 h后股动脉采血处死各组大鼠,取鼠膝关节软骨,采用苏木素-伊红(HE)染色法观察各组软骨的病理改变,并进行Mankin评分;免疫组化法检测各组关节软骨组织中STAT3,超氧化物歧化酶3(SOD3)和Wnt抑制因子1(WIF1)的表达;实时荧光定量聚合酶链式反应(Real-time PCR)检测软骨组织中IL-6 mRNA的表达;蛋白免疫印迹法(Western blot)检测各组关节软骨组中WIF1蛋白的表达。结果:与假手术组比较,模型组大鼠软骨组织Makin评分明显升高,软骨组织STAT3在蛋白水平上的表达明显增加和IL-6 mRNA水平上的表达显著增加,WIF1在蛋白水平上的表达显著降低(P<0.01);模型组关节软骨边缘严重破坏,软骨细胞排列紊乱。与模型组比较,右归丸高剂量干预组大鼠软骨组织Makin评分,STAT3的在蛋白水平上的表达明显降低,右归丸各干预组IL-6 mRNA水平上的表达显著降低,WIF1在蛋白水平上的表达显著增加(P<0.05,P<0.01),软骨结构趋于正常,软骨细胞分布仅偶见不均,关节软骨表面欠光滑。结论:右归丸能显著改善KOA大鼠的关节软骨退变,抑制KOA中软骨组织的炎症反应,这可能与其抑制STAT3和IL-6的表达有关。     

多囊蛋白在肿瘤研究中的新进展

多囊蛋白（polycystin，PC）作为一个细胞表面的膜受体，是一种位于细胞表面的多功能跨膜蛋白，在多种上皮细胞中表达。作为一种新型的机械敏感分子，参与常染色体显性多囊肾病、多囊肝等疾病中囊肿形成扩张、骨骼生长发育及创伤愈合等多种生理病理过程。近年来研究发现多囊蛋白与肿瘤的发生发展密切相关,通过cAMP/PKA、Wnt/β-catenin、mTOR、GSK3β等多个信号传导通路，参与肿瘤细胞的增殖、黏附、凋亡及迁移过程，并与肿瘤治疗及预后相关。现总结近年来PC在肿瘤中的生物学作用及研究进展作一综述。     

Notch信号通路可通过激活Slug调控骨肉瘤上皮-间质转化

目的 探究Notch信号通路对骨肉瘤上皮-间质转化的影响及其机制。方法 通过慢病毒转染技术转染骨肉瘤细胞，利用si-slug敲除Slug基因，采用免疫荧光染色技术、Western blot、qRT-PCR、相差显微镜、划痕实验和TranswellTM实验检测相应骨肉瘤细胞形态、侵袭、转移及上皮间质转化（EMT）情况。动物实验比较各组小鼠成瘤后体积、重量变化；采用qRT-PCR检测离体肿瘤组织中Slug和N-cadherin的表达。结果 成功得到Notch信号通路激活或抑制的骨肉瘤细胞，Notch信号通路激活组E-cadherin表达无明显变化，N-cadherin表达显著升高，骨肉瘤细胞长/短轴比率上调，Slug、Twist1表达上调，侵袭及转移能力增强。动物实验发现Notch信号通路激活可促进体内成瘤，离体骨肉瘤组织中Slug、N-cadherin阳性率增高。Slug被成功敲除后Notch信号激活组骨肉瘤细胞形态、侵袭及转移能力发生逆转。结论 Notch信号通路对骨肉瘤上皮-间质转化过程具有促进作用，其机制可能与激活Slug有关。     

藿香正气汤抑制新型冠状病毒复制过程的有效成分及机制初探＊

目的 收集藿香正气汤的主要活性成分，通过分子对接及网络药理学探讨其防控新型冠状病毒肺炎（COVID-19）的有效成分及治疗机制。方法 通过基于配体-蛋白质相互作用的计算方法，以瑞德西韦为对照，探索藿香正气汤潜在治疗COVID-19的成分，并选出对接较好成分进行药理学机制预测，初探其药理学机制。结果 本研究筛选出5种与新冠病毒3CLpro结合能力强于瑞德西韦的小分子成分。网络药理学初步预测抗病毒途径可能是通过PI3K-Akt 信号通路影响病毒复制。结论 成分C1-C5与3CLpro结合良好，推测其可能是潜在的3CLpro的抑制剂，为抗病毒天然药物的开发提供了理论依据。     

circZBTB44通过调控AKT通路促进肾透明细胞癌增殖和迁移的研究

目的 探究circZBTB44在肾透明细胞癌中的表达情况及探讨circZBTB44在肾透明细胞癌中的生物学功能及促进肾透明细胞癌细胞进展的可能机制。方法 通过qRT-PCR法检测circZBTB44在我院21对肾透明细胞癌组织及细胞系786-O、ACHN中的表达水平;通过放线菌素D实验、RNase R实验、核浆分离实验鉴定circZBTB44的特征;通过siRNA下调circZBTB44的表达后,通过MTS细胞增殖实验、克隆形成实验及Transwell迁移实验来探究circZBTB44对肾透明细胞癌786-O、ACHN的生物学功能影响;通过蛋白免疫印迹实验来探究circZBTB44调控的下游通路。结果 circZBTB44在肾透明细胞癌组织和细胞株786-O和ACHN中明显高表达。下调circZBTB44的表达可明显抑制786-O和ACHN的增殖和迁移能力。下调circZBTB44可抑制肾透明细胞癌786-O和ACHN细胞中AKT的磷酸化。结论 circZBTB44在肾透明细胞癌中高表达。circZBTB44可能通过调控AKT信号通路促进肾透明细胞癌的增殖和迁移。     

Fatal unexpected death due to X-linked lymphoproliferative disease

X-linked lymphoproliferative disease (XLP) is a rare immunodeficiency disease characterized by severe immune disorder and extreme vulnerability to Epstein-Barr virus (EBV) infections. Here we report a 14-month-old Chinese boy presenting with fulminant infectious mononucleosis (FIM) following EBV infection, and died of hepatic failure within one week of disease progression. Postmortem examination revealed icterus, ascites, extensive enlarged mesenteric lymph nodes and hepatosplenomegaly. Histopathological examination showed diffuse proliferation of cytotoxic T lymphoid cells and hemophagocytosis in multiple organs. The family history revealed his brother had died under similar circumstances at 5 five years of age. The cause of death of the boy was ascribed to XLP. To the best of our knowledge, there is few autopsy-confirmed XLP case in the forensic practice. The complicated manifestations and systemic pathological changes should be well recognized by clinicians and forensic pathologists.     

An evaluation of glasdegib for the treatment of acute myelogenous leukemia

ABSTRACT

Introduction

Despite recent advances in the treatment of adult acute myelogenous leukemia (AML), the overall outcome remains dismal especially in high-risk AML patients, including the elderly and the relapsed/refractory populations. In this setting, various clinical trials have recently explored novel therapeutic agents either used alone or in combination with intensive chemotherapy or low-intensity treatments.     

脑梗死合并肺部感染患者TNF-α、HMGBl、TLR4-NF-κB信号通路改变研究

目的探究脑梗死合并肺部感染患者的肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)和高迁移率族蛋白Bl(High mobility group protein Bl,HMGBl)水平及其临床价值研究。方法2018年1月-2019年2月儋州市人民医院收治的急性脑梗死患者作为研究对象,其中急性脑梗死合并肺部感染患者30例作为感染组,急性脑梗死无肺部感染患者80例作为非感染组,选择同期于此医院体检的健康者30名作为对照组。采用酶联免疫吸附法(Enzyme-linked immuno sorbent assay,ELISA)检测血清HMGB1和细胞因子IL-6、TNF-α水平,采用Western Blot法检测血清Toll样家族受体-4(Toll like receptor-4,TLR4)、核因子κB(nuclear factor kappa-B,NF-κB)、髓样分化因子(myeloiddifferentiationfactor88,MyD88)表达水平。结果感染组的血清HMGB1、TLR4、NF-κB、MyD88表达及细胞因子IL-6、TNF-α水平均高于非感染组和对照组(P<0.05);感染组患者大梗死灶、中等梗死灶、小梗死灶各指标总体水平差异具有统计学意义(P<0.05)。大梗死灶、中等梗死灶两亚组患者的血清HMGB1、TLR4、NF-κB、MyD88表达及细胞因子IL-6、TNF-α水平均高于小梗死灶亚组(P<0.05);急性脑梗死合并肺部感染患者的血清HMGB1和TNF-α水平呈正相关(r=0.523,P<0.001)。结论脑梗死合并肺部感染患者伴随TNF-α、HMGBl、TLR4-NF-κB信号通路的明显改变,且与梗死灶大小具有相关性,其机制有待进一步研究。